Longeveron Inc. (LGVN)
NASDAQ: LGVN · Real-Time Price · USD
1.650
+0.050 (3.13%)
At close: Dec 20, 2024, 4:00 PM
1.660
+0.010 (0.61%)
After-hours: Dec 20, 2024, 6:26 PM EST
Longeveron Employees
As of December 31, 2023, Longeveron had 24 total employees, including 23 full-time and 1 part-time employees. The number of employees increased by 3 or 14.29% compared to the previous year.
Employees
24
Change (1Y)
3
Growth (1Y)
14.29%
Revenue / Employee
$77,167
Profits / Employee
-$1,107,083
Market Cap
24.48M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 24 | 3 | 14.29% |
Dec 31, 2022 | 21 | 1 | 5.00% |
Dec 31, 2021 | 20 | 8 | 66.67% |
Dec 31, 2020 | 12 | -4 | -25.00% |
Dec 31, 2019 | 16 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Co-Diagnostics | 155 |
Vivos Therapeutics | 123 |
Pluri | 118 |
PolyPid | 62 |
Cara Therapeutics | 55 |
NeuroSense Therapeutics | 18 |
Lipocine | 17 |
NeuroOne Medical Technologies | 16 |
LGVN News
- 3 days ago - Longeveron to Present at Biotech Showcase 2025 - GlobeNewsWire
- 19 days ago - Longeveron to Present at the Emerging Growth Virtual Conference on December 5, 2024 - GlobeNewsWire
- 5 weeks ago - Longeveron, Inc. (LGVN) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Longeveron® Appoints Devin Blass as Chief Technology Officer and SVP of Chemistry, Manufacturing and Controls (CMC) - GlobeNewsWire
- 6 weeks ago - Longeveron® to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024 - GlobeNewsWire
- 7 weeks ago - Longeveron® Presents Lomecel-B™ Data for Alzheimer's Disease Indication in Late Breaking Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD24) - GlobeNewsWire
- 7 weeks ago - Longeveron® Presents Lomecel-B™ Long-term Transplant-free Survival Data in Hypoplastic Left Heart Syndrome (HLHS) at the Congenital Heart Surgeons' Society (CHSS) 51st Annual Meeting - GlobeNewsWire
- 2 months ago - Longeveron® Lomecel-B™ Data in Alzheimer's Disease Selected for Late Breaking Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD24) - GlobeNewsWire